Aryl hydrocarbon receptor is a prognostic biomarker and is correlated with immune responses in cervical cancer

Wang, Jiasui; Mijiti, Yilidana; Chen, Yalin; Liu, Zaoling

doi:10.1080/21655979.2021.2006953

Cited by 10 publications

(2 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In BRCA, upregulation of PTGES3 was significantly correlated to CD8+ T cell abundance in TME, suggesting that PTGES3 could be an immune regulator. In addition, it was revealed that PTGES3 was negatively associated with immunoinhibitors, immunostimulators, and Major Histocompatibility Complex molecules in cervical cancer [ 43 ]. However, the relationship between PTGES3 expression and immune regulation in LUAD has not yet been studied.…”

Section: Discussionmentioning

confidence: 99%

Effect of PTGES3 on the Prognosis and Immune Regulation in Lung Adenocarcinoma

Jiang

Wei

Xie

et al. 2023

Analytical Cellular Pathology

View full text Add to dashboard Cite

Background. PTGES3 is upregulated in multiple cancer types and promotes tumorigenesis and progression. However, the clinical outcome and immune regulation of PTGES3 in lung adenocarcinoma (LUAD) are not fully understood. This study aimed to explore the expression level and prognostic value of PTGES3 and its correlation with potential immunotherapy in LUAD. Methods. All data were obtained from several databases, including the Cancer Genome Atlas database. Firstly, gene and protein expression of PTGES3 were analyzed using Tumor Immune Estimation Resource (TIMER), R software, Clinical Proteomic Tumor Analysis Consortium (CPTAC), and Human Protein Atlas (HPA). Thereafter, survival analysis was conducted using the R software, Gene Expression Profiling Interactive Analysis 2 (GEPIA2), and Kaplan–Meier Plotter. In addition, gene alteration and mutation analyses were conducted using the cBio Cancer Genomics Portal (cBioPortal) and Catalog of Somatic Mutations in Cancer (COSMIC) databases. The molecular mechanisms associated with PTGES3 were assessed via Search Tool for the Retrieval of Interacting Genes/Proteins (STRING), GeneMANIA, GEPIA2, and R software. Lastly, the role of PTGES3 in immune regulation in LUAD was investigated using TIMER, Tumor-Immune System Interaction Database (TISIDB), and SangerBox. Results. The gene and protein expression of PTGES3 were elevated in LUAD tissues and compared to the normal tissues, and the high expression of PTGES3 was correlated with cancer stage and tumor grade. Survival analysis revealed that overexpression of PTGES3 was associated with poor prognosis of LUAD patients. Moreover, gene alteration and mutation analysis revealed the occurrence of several types of PTGES3 gene alterations in LUAD. Moreover, co-expression analysis and cross-analysis revealed that three genes, including CACYBP, HNRNPC, and TCP1, were correlated and interacted with PTGES3. Functional analysis of these genes revealed that PTGES3 was primarily enriched in oocyte meiosis, progesterone-mediated oocyte maturation, and arachidonic acid metabolism pathways. Furthermore, we found that PTGES3 participated in a complex immune regulation network in LUAD. Conclusion. The current study indicated the crucial role of PTGES3 in LUAD prognosis and immune regulation. Altogether, our results suggested that PTGES3 could serve as a promising therapeutic and prognosis biomarker for the LUAD.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of PTGES3 on the Prognosis and Immune Regulation in Lung Adenocarcinoma

Jiang

Wei

Xie

et al. 2023

Analytical Cellular Pathology

View full text Add to dashboard Cite

show abstract

“…TDO is a critical prognostic oncolytic biomarker, as its overexpression correlates with poor overall and progression-free survival [97]. Mechanistically, TDO catabolizes Trp to Kyn, a binding ligand for the aryl hydrocarbon receptor (AHR), which is involved in multiple bioregulatory processes contributing to CC progression [98,99]. Details of the AHR pathway and its role in cancer progression are beyond the scope of this review but are extensively discussed elsewhere [100,101].…”

Section: Immunopathogenesismentioning

confidence: 99%

TIME Is Ticking for Cervical Cancer

Kumar

Bauer

Stewart

2023

Biology

View full text Add to dashboard Cite

Cervical cancer (CC) is a major health problem among reproductive-age females and comprises a leading cause of cancer-related deaths. Human papillomavirus (HPV) is the major risk factor associated with CC incidence. However, lifestyle is also a critical factor in CC pathogenesis. Despite HPV vaccination introduction, the incidence of CC is increasing worldwide. Therefore, it becomes critical to understand the CC tumor immune microenvironment (TIME) to develop immune cell-based vaccination and immunotherapeutic approaches. The current article discusses the immune environment in the normal cervix of adult females and its role in HPV infection. The subsequent sections discuss the alteration of different immune cells comprising CC TIME and their targeting as future therapeutic approaches.

show abstract

Unveiling the Immune effects of AHR in tumors: a decade of insights from bibliometric analysis (2010–2023)

Xie,

Wang,

Shi

et al. 2024

Discov Onc

View full text Add to dashboard Cite

Background The Aryl Hydrocarbon Receptor (AHR) is a transcription factor that regulates several biological processes. Its potential in anti-tumor immunotherapy is becoming clearer, yet no bibliometric studies on this topic exist. This study aims to understand the current research landscape and identify future directions through a bibliometric analysis of AHR’s anti-tumor immunological effects. Methods We conducted a comprehensive bibliometric analysis of AHR antitumor immunotherapy papers in the Web of Science Core Collection. Various aspects of the publications were analyzed, and research hotspots and future trends were identified using scientific bibliometric tools and statistical methods. Results We collected 592 English papers published between 2010 and 2023, with an almost annual increase. Most publications were from the USA, followed by China, Germany, and Italy. The journal “Frontiers in Immunology” had the most papers, and the most cited paper was Christiane A. Opitz’s “An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor.” The research is centered around AHR gene expression, with a growing focus on intestinal disease and the development of Programmed cell death ligand 1 (PD-L1) drugs. Conclusion This bibliometric study highlights the significance of AHR in immunomodulatory research, outlining the research trends and key contributors. It suggests AHR’s immune effects may mediate the process of colitis cancer transformation, providing valuable insights for future anti-tumor immunotherapy strategies based on AHR.

show abstract

Aryl hydrocarbon receptor is a prognostic biomarker and is correlated with immune responses in cervical cancer

Cited by 10 publications

References 46 publications

Effect of PTGES3 on the Prognosis and Immune Regulation in Lung Adenocarcinoma

Effect of PTGES3 on the Prognosis and Immune Regulation in Lung Adenocarcinoma

TIME Is Ticking for Cervical Cancer

Unveiling the Immune effects of AHR in tumors: a decade of insights from bibliometric analysis (2010–2023)

Contact Info

Product

Resources

About